Patents by Inventor Fubin Li
Fubin Li has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 12145993Abstract: Provided herein is a heavy chain constant region comprising a CH1 domain, a hinge region, a CH2 domain and a CH3 domain, wherein the sequences of said CH1 domain and hinge region derive from the sequences of CH1 domain and hinge region in human IgG2, the sequences of said CH2 domain and CH3 domain derive from the sequences of CH2 domain and CH3 domain in human IgGs; and wherein, said antibody heavy chain constant region has an affinity to human Fc?RIIB equal to or higher than the affinity of human IgG1 to human Fc?RIIB, said antibody heavy chain constant region has an I/A ratio equal to or higher than human IgG1 has. Also provided are antibodies or fusion proteins based on a heavy chain constant region according to the above, wherein the antibody heavy chain constant region significantly enhances agonistic activity of the antibodies or fusion proteins and improves efficacy of the antibodies or fusion proteins in treating diseases like tumors and autoimmune diseases.Type: GrantFiled: June 8, 2017Date of Patent: November 19, 2024Assignee: SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINEInventors: Fubin Li, Xiaobo Liu, Yan Zhang, Yingjie Zhao, Huan Shi, Huihui Zhang
-
Publication number: 20240209104Abstract: Provided are an anti-OX40 antibody, and a pharmaceutical composition and application thereof. The anti-OX40 antibody or an antigen-binding fragment and pharmaceutical composition thereof can be used for treating a T cell-related disease.Type: ApplicationFiled: August 26, 2021Publication date: June 27, 2024Inventors: See Heng WONG, Jianliang LI, Fubin LI, Wei CAI, Xiaohua YAN, Meng TIAN, Junxia ZHANG, Yanxia BI, Caihong WANG
-
Publication number: 20230220042Abstract: Provided is a modified Fc region. The Fc region has at least one amino acid mutation with respect to a parent Fc region. The modified Fc region has improved affinity to Fc?RIIB with respect to the affinity of the parent Fc region to Fc?RIIB Also provided is an antibody containing the modified Fc region, especially an agonistic antibody. The modified Fc region has significant use for optimizing the agonistic activity of the antibody.Type: ApplicationFiled: December 3, 2020Publication date: July 13, 2023Applicant: SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINEInventors: Fubin LI, Yan ZHANG, Mi ZHANG, Yanxia BI, Shihao TIAN, Huihui ZHANG, Shujun LIU
-
Publication number: 20190263918Abstract: Provided herein is a heavy chain constant region comprising a CH1 domain, a hinge region, a CH2 domain and a CH3 domain, wherein the sequences of said CH1 domain and hinge region derive from the sequences of CH1 domain and hinge region in human IgG2, the sequences of said CH2 domain and CH3 domain derive from the sequences of CH2 domain and CH3 domain in human IgGs; and wherein, said antibody heavy chain constant region has an affinity to human Fc?RIIB equal to or higher than the affinity of human IgG1 to human Fc?RIIB, said antibody heavy chain constant region has an I/A ratio equal to or higher than human IgG1 has. Also provided are antibodies or fusion proteins based on a heavy chain constant region according to the above, wherein the antibody heavy chain constant region significantly enhances agonistic activity of the antibodies or fusion proteins and improves efficacy of the antibodies or fusion proteins in treating diseases like tumors and autoimmune diseases.Type: ApplicationFiled: June 8, 2017Publication date: August 29, 2019Inventors: Fubin LI, Xiaobo LIU, Yan ZHANG, Yingjie ZHAO, Huan SHI, Huihui ZHANG
-
Patent number: 10140244Abstract: An optical module and a method of transmitting data in the optical module are provided in the present disclosure. According to an example, the optical module may comprise a micro controller unit (MCU) and N number of first driving chips having a same chip address. The MCU may be configured with a serial data (SDA) bus interface and N number of first serial clock (SCL) bus interfaces. Each of the N number of first driving chips may be configured with a SDA bus interface which is configured to be connected with the SDA bus interface on the MCU and a SCL bus interface which is configured to be connected with one of the N number of first SCL bus interfaces on the MCU.Type: GrantFiled: December 27, 2016Date of Patent: November 27, 2018Assignees: HISENSE BROADBAND MULTIMEDIA TECHNOLOGIES CO., LTD., HISENSE BROADBAND MULTIMEDIA TECHNOLOGIES, LTD.Inventors: Fengmei Fan, Fubin Li
-
Publication number: 20170337153Abstract: An optical module and a method of transmitting data in the optical module are provided in the present disclosure. According to an example, the optical module may comprise a micro controller unit (MCU) and N number of first driving chips having a same chip address. The MCU may be configured with a serial data (SDA) bus interface and N number of first serial clock (SCL) bus interfaces. Each of the N number of first driving chips may be configured with a SDA bus interface which is configured to be connected with the SDA bus interface on the MCU and a SCL bus interface which is configured to be connected with one of the N number of first SCL bus interfaces on the MCU.Type: ApplicationFiled: December 27, 2016Publication date: November 23, 2017Applicants: Hisense Broadband Multimedia Technologies Co., Ltd., Hisense Broadband Multimedia Technologies. Ltd.Inventors: Fengmei Fan, Fubin LI
-
Publication number: 20170247463Abstract: The instant invention relates to agents (e.g., agonistic antibodies) able to stimulate the immune system of a mammalian animal and activate target-cell specific T lymphocyte responses. Such agents may be identified based on the ability to engage a receptor from the TNFR Superfamily and thereby mimic the natural ligand for the receptor from the TNFR Superfamily. Modified antibodies of this class display enhanced immunostimulatory activity and may be formulated and administered for the treatment of a disease or disorder.Type: ApplicationFiled: February 6, 2017Publication date: August 31, 2017Applicant: The Rockefeller UniversityInventors: Jeffrey V. Ravetch, Fubin Li
-
Patent number: 9167743Abstract: A greening roll includes water-temperature-light controlling part, root growing part, water/root regulating part and seed-stacking part which is located in the water-temperature-light controlling part. The water-temperature-light controlling part is located on the top surface of the greening roll, the water/root regulating part is located on the lower surface of the greening roll, the root growing part is located in the cavity composed by the water-temperature-light controlling part and the water/root regulating part, and the seed-stacking part is located in the cavity of the water-temperature-light controlling part. The water-temperature-light controlling part further includes top-located irradiation reflecting part, temperature-water regulating part, light-preventing part and seed-stacking cavity.Type: GrantFiled: February 22, 2012Date of Patent: October 27, 2015Inventors: Shaocai Li, Hailong Sun, Feng Long, Fubin Li
-
Publication number: 20140059926Abstract: A greening roll includes water-temperature-light controlling part, root growing part, water/root regulating part and seed-stacking part which is located in the water-temperature-light controlling part. The water-temperature-light controlling part is located on the top surface of the greening roll, the water/root regulating part is located on the lower surface of the greening roll, the root growing part is located in the cavity composed by the water-temperature-light controlling part and the water/root regulating part, and the seed-stacking part is located in the cavity of the water-temperature-light controlling part. The water-temperature-light controlling part further includes top-located irradiation reflecting part, temperature-water regulating part, light-preventing part and seed-stacking cavity.Type: ApplicationFiled: February 22, 2012Publication date: March 6, 2014Inventors: Shaocai Li, Hailong Sun, Feng Long, Fubin Li
-
Publication number: 20140010812Abstract: The instant invention relates to agents (e.g., agonistic antibodies) able to stimulate the immune system of a mammalian animal and activate target-cell specific T lymphocyte responses. Such agents may be identified based on the ability to engage a receptor from the TNFR Superfamily and thereby mimic the natural ligand for the receptor from the TNFR Superfamily. Modified antibodies of this class display enhanced immunostimulatory activity and may be formulated and administered for the treatment of a disease or disorder.Type: ApplicationFiled: December 19, 2011Publication date: January 9, 2014Applicant: ROCKEFELLER UNIVERSITY (THE)Inventors: Jeffrey V. Ravetch, Fubin Li